HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association sponsored the 94th Annual First Ladies Luncheon in Washington, D.C. April 27 as part of effort to communicate to Congress "the tremendous contribution that personal care and cosmetics products make to the well-being and self esteem of women across America," according to CTFA President Pam Bailey. Proceeds of the event, which was organized by the nonprofit Congressional Club of Washington D.C. in honor of the First Lady, were donated to a charity. Bailey has stressed the importance of improving CTFA's visibility among legislators (1"The Rose Sheet" Jan. 16, 2006, p. 4)...

You may also be interested in...

CTFA Stresses Importance Of FD&C Act In Congressional Outreach

The Cosmetic, Toiletry and Fragrance Association will work this year to communicate to Congress the value of the FD&C Act in regulating cosmetic safety, according to CTFA President Pam Bailey

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts